

Nordic Summerschool of Cancer Epidemiology

Bendix Carstensen Steno Diabetes Center
Gentofte, Denmark
<http://BendixCarstensen.com>
Esa Läärä University of Oulu
Oulu, Finland

Danish Cancer Society / NCU, August 2019 / January 2020

From /home/bendix/teach/NSCE/2019/slides/slides.tex

Saturday 10th August, 2019, 17:47

1/ 149

Introduction

- ▶ Starters
- ▶ Analysis and statistics
- ▶ Uses of statistics in epidemiology
- ▶ References

2/ 149

Cohort of male asbestos workers, $N = 17800$.

Observed $D = 24$ cases of lung cancer deaths.

Expected $E = 7$ cases based on age-specific rates in general population.

$$\text{SMR} = \frac{D}{E} = \frac{24}{7} = 3.4$$

Observed rate ratio > 1 :

- ▶ true as such?
- ▶ biased? by which factors?
- ▶ due to play of chance?

3/ 149

Nurses Health Study (NHS) on oral contraceptive (OC) use and breast cancer.

Null hypothesis H_0 :

OC use does not affect risk of breast cancer; true rate ratio = 1 between ever and never users.

Summary of study outcomes:

OC use	No. of Cases	Person-years	Rate (/10 ⁵ y)
Ever	204	94,029	217
Never	240	128,528	187

4/ 149

Results:

- ▶ Observed rate ratio $RR = 217/187 = 1.16$
- ▶ P -value 0.12
- ▶ 95% confidence interval [0.96, 1.40]

Interpretation?

- ▶ true rate ratio = 1.16?
- ▶ probability that H_0 is true = 12% ?
- ▶ probability = 95%, that true rate ratio is between 0.96 and 1.40?
- ▶ other? further analysis needed?

5/ 149

Analysis and statistics

By **analysis** we mean **statistical** analysis.

Statistics:

- ▶ (singular) the science that deals with the:
 - ▶ collection, classification, analysis, and interpretation of numerical facts or data, and that,
 - ▶ by use of mathematical theories of probability, imposes order and regularity on aggregates of more or less disparate elements.
- ▶ (plural) the numerical facts or data themselves

(Webster's Dictionary)

6/ 149

Use of statistics in epidemiology

- ▶ assessment of **random variation**
- ▶ control of **confounding** and
- ▶ evaluation of **effect modification** (a.k.a. interaction)
- ▶ guiding study planning:
choice of design, group sizes
length of follow-up, sampling

7 / 149

Use of statistics

Basic approaches and tools:

- ▶ descriptive summarization of data
- ▶ mathematical models for random variation
- ▶ statistical inference: estimation and testing
- ▶ crude and stratified analysis
- ▶ regression methods.

8 / 149

References

- IS:** dos Santos Silva, I. (1999).
Cancer Epidemiology: Principles and Methods.
International Agency for Research on Cancer, Lyon.
- B&D:** Breslow, N.E., Day, N.E. (1987).
Statistical Methods in Cancer Research Volume II – The Design and Analysis of Cohort Studies. IARC, Lyon.
- C&H:** Clayton, D., Hills, M. (1993).
Statistical Models in Epidemiology. OUP, Oxford.

9 / 149

Chance

Bendix Carstensen & Esa Läärä

Nordic Summerschool of
Cancer Epidemiology
Danish Cancer Society / NCU, August 2019 / January 2020

<http://BendixCarstensen.com/NSCE/2019>

chance

Chance variation

- ▶ Systematic and random variation
- ▶ Probability model:
 - ▶ random variable — observation — data
 - ▶ distribution
 - ▶ parameters
- ▶ Statistic
- ▶ Standard error

Chance (chance)

10 / 149

Systematic and random variation

Cancer incidence rates vary by known & measured determinants of disease, such as:

- ▶ age,
- ▶ gender,
- ▶ region,
- ▶ time,
- ▶ specific risk factors.

This is **systematic variation**.

Chance (chance)

11 / 149

Systematic and random variation

In addition, observed rates are subject to **random** or **chance variation**:

- variation due to unknown sources like
 - ▶ latent genetic differences,
 - ▶ unknown concomitant exposures,
 - ▶ sampling,
 - ▶ "pure chance" — quantum mechanics

Example: Smoking and lung cancer

- ▶ Only a minority of smokers get lung cancer
- ▶ . . . and some non-smokers get the disease, too.
- ▶ At the **individual** level the outcome is unpredictable.
- ▶ When cancer occurs, it can eventually only be explained just by "bad luck".
- ▶ Unpredictability of individual outcomes implies largely unpredictable — **random** — variation of disease rates at population level.

Example: Breast cancer

Breast cancer incidence rates in Finland, age group 65-69 years in three successive years.

Year	Males (per 10 ⁶ P-years)	Females (per 10 ⁴ P-years)
1989	46	21
1990	11	20
1991	33	19

- ▶ Big annual changes in risk among males?
- ▶ Is there steady decline in females?

Example: Breast cancer

Look at observed numbers of **cases!**

Year	Males		Females	
	Cases	P-years	Cases	P-years
1989	4	88,000	275	131,000
1990	1	89,000	264	132,000
1991	3	90,000	253	133,000

Reality of changes over the years?

The information is in the number of **cases**

Simple probability model for cancer occurrence

Assume that the population is **homogeneous**

- ▶ the theoretical incidence rate
- ▶ **hazard** or **intensity** — λ
- ▶ of contracting cancer
- ▶ is **constant** over a short period of time, dt

$$\lambda = \Pr\{\text{Cancer in}(t, t + dt)\}/dt$$

Simple probability model for cancer occurrence

- ▶ The observations:
 - ▶ Number of cases D in
 - ▶ Y person-years at risk
 - ▶ \Rightarrow empirical incidence rate $R = D/Y$
- ▶ are all **random variables** with unpredictable values
- ▶ The **probability distribution** of possible values of a random variable has some known mathematical form
- ▶ ... some properties of the probability distribution are determined by the **assumptions**
- ▶ ... other properties are determined by quantities called **parameters**
- ▶ — in this case the theoretical rate λ .

How a probability model works

If the hazard of lung cancer, λ , is constant over time, we can **simulate** lung cancer occurrence in a population:

- ▶ Start with N persons,
- ▶ 1st day: $P \{\text{lung cancer}\} = \lambda \times 1 \text{ day}$ for all N persons
- ▶ 2nd day: $P \{\text{lung cancer}\} = \lambda \times 1 \text{ day}$ for those left w/o LC
- ▶ 3rd day: $P \{\text{lung cancer}\} = \lambda \times 1 \text{ day}$ for those left w/o LC
- ▶ ...

Thus a **probability model** shows how to **generate data** with **known parameters**. Model \rightarrow Data

Component of a probability model

- ▶ **structure** of the model
 - *a priori* assumptions:
 - constant incidence rate
- ▶ **parameters** of the model
 - *size* of the incidence rate:
 - derived from data **conditional** on structure

Statistics

The opposite of a probability models:

- ▶ the **data** is known
- ▶ want to find **parameters**
- ▶ this is called estimation
- ▶ ... mostly using maximum likelihood

Thus **statistical modelling** is how to **estimate parameters** from **observed data**. Data \rightarrow Model

Statistics — the workings

- ▶ Fix the **model** (structure)
- ▶ For any set of parameters we can generate data
- ▶ Find parameters that generates data that look most like the observed data
- ▶ Recall the notion of **random variables**:
 - ▶ Given model and parameter
 - ▶ we know the distribution of **functions of data**
- ▶ Essential distributions are **Poisson** and **Normal** (Gaussian) distributions

Chance (chance)

21/ 149


Poisson and Gaussian models

- ▶ **Poisson distribution**: simple probability model for number of cases D (in a fixed follow-up time, Y) with
- ▶ **expectation** (theoretical mean) $\mu = \lambda Y$,
- ▶ **standard deviation** $\sqrt{\mu}$
- ▶ When the expectation μ of D is large enough, the Poisson distribution resembles more and more the **Gaussian** or **Normal** distribution.

Chance (chance)

22/ 149

Poisson distribution with different means (μ)



Chance (chance)

23/ 149


Normal (Gaussian) distribution

- ▶ common model for continuous variables
 - ▶ symmetric and bell-shaped
 - ▶ has two parameters:
 - μ = expectation or mean
 - σ = standard deviation
- ▶ Central limit theorem:
A sum of many small independent quantities will follow a normal distribution
- ▶ Consequence:
When we compute various functions based on our data we can approximate the distribution with the normal distribution
- ▶ ... so we just need to compute mean and standard deviation — the shape is fixed by the theory

Chance (chance)

24/ 149

Areas under curve limited by selected quantiles



Chance (chance)

25/ 149

Example: Observed incidence rate

- ▶ **Model:** incidence rate is constant over time
- ▶ **Theoretical rate** λ ,
- ▶ **Empirical rate** $R = D/Y$,
- ▶ **Estimator** of λ , $\hat{\lambda} = R$.
- ▶ $\hat{\lambda} = R$ is a statistic, random variable:
 - ▶ its value varies from one study population ("sample") to another on hypothetical repetitions
 - ▶ ... namely other similar condition under which data could have been generated
 - ▶ its sampling distribution is (under the constant rate model & other conditions) a transformation of the Poisson distribution

Chance (chance)

26/ 149

Example: Observed incidence rate

- ▶ D approximately Poisson, mean λY , sd $\sqrt{\lambda Y}$
- ▶ $R = D/Y$ scaled Poisson:
mean: λ , sd: $\sqrt{\lambda Y}/Y = \sqrt{\lambda/Y}$
- ▶ Standard error of empirical rate R is estimated by replacing λ with R :

$$\text{s.e.}(R) = \sqrt{\frac{\hat{\lambda}}{Y}} = \sqrt{\frac{R}{Y}} = \frac{\sqrt{D}}{Y} = R \times \frac{1}{\sqrt{D}}$$

- ⇒ Random error depends inversely on the number of cases.
- ⇒ s.e. of R is proportional to R .

Example: Observed incidence rate

- ▶ Use the central limit theorem:
 - ▶ $\hat{\lambda} = R \sim \mathcal{N}(\lambda, \lambda/Y) = \mathcal{N}(\lambda, \lambda^2/D)$
- ⇒ Observed R is with 95% probability in the interval

$$(\lambda - 1.96 \times \lambda/\sqrt{D}; \lambda + 1.96 \times \lambda/\sqrt{D})$$

- ⇒ with 95% probability λ is in the interval

$$(R - 1.96 \times R/\sqrt{D}; R + 1.96 \times R/\sqrt{D})$$

- ▶ ... a 95% confidence interval for the rate.

Chance summary

- ▶ Observations vary systematically by **known** factors
- ▶ Observations vary randomly by **unknown** factors
- ▶ Probability model describes the random variation
- ▶ We observe random variables — draws from a probability distribution
- ▶ Central limit theorem allows us to quantify the random variation
- ▶ ... and construct confidence interval

Inference

Bendix Carstensen & Esa Läärä

Nordic Summerschool of
Cancer Epidemiology
Danish Cancer Society / NCU, August 2019 / January 2020

<http://BendixCarstensen.com/NSCE/2019>

inference

Models and data

- ▶ Probability model can be used to generate data (by simulation) — from **model** to **data**
- ▶ Inference is the **inverse**:
- ▶ What model generated the data?
- ▶ — from data to model
- ▶ ... if we know that we can say something sensible about disease process in the population

Inference (inference)

30 / 149

Models and data — model components

- ▶ External, *a priori* information on observations — structure of the model
- ▶ quantitative parameter(s) within model structure
- ▶ only the latter is the target for inference

Inference (inference)

31 / 149

Statistical concepts

- ▶ Probability: parameters \rightarrow data
- ▶ Statistics: data \rightarrow parameter(estimate)s
- ▶ Notation:
 - ▶ Parameter denoted by a Greek letter, β
 - ▶ Estimator & estimate by the same Greek letter with "hat", $\hat{\beta}$
- ▶ Ex: Incidence rate:
 - ▶ Theoretical rate — the rate in the model that could have generated data: λ
 - ▶ Estimator: $\hat{\lambda} = R = D/Y$, empirical rate.
- ▶ ... but where did the D/Y come from?

Inference (inference)

32/ 149

Maximum likelihood principle

- ▶ Define your model (e.g. constant rate)
- ▶ Choose a parameter value
- ▶ How likely is it that
 - this model with
 - this parametergenerated data
- ▶ $P\{\text{data}|\text{parameter}\}$, $P\{(d, y)|\lambda\}$
- ▶ Find the parameter value that gives the maximal probability of data
- ▶ Find the interval of parameter values that give probabilities not too far from the maximum.

Inference (inference)

33/ 149

Likelihood

Probability of the data given the parameter:

Assuming the rate (intensity) is constant, λ , the probability of observing 14 deaths in the course of 843.6 person-years:


$$\begin{aligned}P\{D = 14, Y = 843.6|\lambda\} &= \lambda^D e^{-\lambda Y} \times K \\ &= \lambda^{14} e^{-\lambda \times 843.6} \times K \\ &= L(\lambda|\text{data})\end{aligned}$$

- ▶ Estimate of λ is where this function is as large as possible.
- ▶ Confidence interval is where it is not too far from the maximum


Inference (inference)

34/ 149


Likelihood function, 14 events, 843.6 PY




Likelihood function, 14 events, 843.6 PY



Log-likelihood function 14 events, 843.6 PY




Log-likelihood function 14 events, 843.6 PY



Inference (inference)

36/ 149


Log-likelihood function 14 events, 843.6 PY



Inference (inference)

36/ 149


Log-likelihood function 14 events, 843.6 PY



Inference (inference)

36/ 149

Log-likelihood function 14 events, 843.6 PY



Inference (inference)

36/ 149

Confidence interval for a rate

- ▶ Based on the [quadratic approximation](#) to the normal density
- ▶ A 95% confidence interval for the log of a rate is:

$$\hat{\theta} \pm 1.96/\sqrt{D} = \log(\hat{\lambda}) \pm 1.96/\sqrt{D}$$

— the 1.96 is from the normal distribution, that is what it is used for.

- ▶ Take the exponential to get the confidence interval for the rate:

$$\hat{\lambda} \times \underbrace{\exp(1.96/\sqrt{D})}_{\text{error factor, erf}}$$

— the probability that the theoretical rate λ is in this interval is 95%.

Inference (inference)

37/ 149

Example for a single rate

Suppose we have 14 deaths during 843.6 years of follow-up.

The rate is computed as:

$$\hat{\lambda} = D/Y = 14/843.6 = 0.0165 = 16.5 \text{ per 1000 years}$$

The confidence interval is computed as:

$$\hat{\lambda} \times \text{erf} = 16.5 \times \exp(1.96/\sqrt{14}) = (9.8, 28.0)$$

per 1000 person-years.

Inference (inference)

38/ 149

Ratio of two rates

If we have observations of two rates λ_1 and λ_0 , based on (D_1, Y_1) and (D_0, Y_0) , the variance of the difference of the log-rates, $\log(\lambda_1) - \log(\lambda_0) = \log(\text{RR})$, is:

$$\begin{aligned}\text{var}(\log(\text{RR})) &= \text{var}(\log(\lambda_1/\lambda_0)) \\ &= \text{var}(\log(\lambda_1)) + \text{var}(\log(\lambda_0)) \\ &= 1/D_1 + 1/D_0\end{aligned}$$

As before a 95% c.i. for the RR is then, using the normal distribution:

$$\text{RR} \times \underbrace{\exp\left(1.96\sqrt{\frac{1}{D_1} + \frac{1}{D_0}}\right)}_{\text{error factor}}$$

Difference of two rates

If we have observations of two rates λ_1 and λ_0 , based on (D_1, Y_1) and (D_0, Y_0) , the variance of the difference of the rates, $\lambda_1 - \lambda_0 = \text{RD}$, is:

$$\begin{aligned}\text{var}(\text{RD}) &= \text{var}(\lambda_1 - \lambda_0) \\ &= \text{var}(\lambda_1) + \text{var}(\lambda_0) \\ &= D_1/Y_1^2 + D_0/Y_0^2\end{aligned}$$

As before a 95% c.i. for the RD is then, using the normal distribution:

$$\text{RD} \pm 1.96\sqrt{\frac{D_1}{Y_1^2} + \frac{D_0}{Y_0^2}}$$

Example

Suppose we in group 0 have 14 deaths during 843.6 years of follow-up in one group, and in group 1 have 28 deaths during 632.3 years.

The rate-ratio is computed as:

$$\begin{aligned}\text{RR} &= \hat{\lambda}_1/\hat{\lambda}_0 = (D_1/Y_1)/(D_0/Y_0) \\ &= (28/632.3)/(14/843.6) = 0.0443/0.0165 = 2.669\end{aligned}$$

The 95% confidence interval is computed as:

$$\begin{aligned}\hat{\text{RR}} \times \text{erf} &= 2.669 \times \exp(1.96\sqrt{1/14 + 1/28}) \\ &= 2.669 \times 1.899 = (1.40, 5.07)\end{aligned}$$

Estimating a rate using R

Poisson likelihood for one rate, based on 14 events in 843.6 PY:

```
> library( Epi )
> D <- 14 ; Y <- 843.6
> m1 <- glm( D ~ 1, offset=log(Y/1000), family=poisson)
> ci.exp( m1 )
```

```
              exp(Est.)    2.5%    97.5%
(Intercept) 16.59554 9.82875 28.02107
```

Conventional description for mortality rates:

“We used Poisson regression with log-person-years as offset...”

But really both D and Y are outcomes (random variables)

Inference (inference)

42/ 149

Estimating a rate using R

But really both D and Y are outcomes (random variables)

```
> mm <- glm( cbind(D,Y/1000) ~ 1, family=poisreg )
> ci.exp( mm )
```

```
              exp(Est.)    2.5%    97.5%
(Intercept) 16.59554 9.82875 28.02107
```

... then you write:

“We used multiplicative Poisson regression for events and person-years...”

Inference (inference)

43/ 149

RR example using R

Poisson likelihood, two rates, or one rate and RR:

```
> D <- c(14,28) ; Y <- c(843.6,632.3) ; gg <- factor(0:1)
> m2 <- glm( cbind(D,Y/1000) ~ gg, family=poisreg )
> ci.exp( m2 )
```

```
              exp(Est.)    2.5%    97.5%
(Intercept) 16.595543 9.828750 28.021066
gg1         2.668354 1.404825 5.068325
```

```
> m3 <- glm( cbind(D,Y/1000) ~ gg - 1, family=poisreg )
> ci.exp( m3 )
```

```
              exp(Est.)    2.5%    97.5%
gg0 16.59554 9.82875 28.02107
gg1 44.28278 30.57545 64.13525
```

Inference (inference)

44/ 149

Statistical tests

- ▶ Are the observed data consistent with a given value of the parameter?
- ▶ Such a value is often a **null value**
- ▶ Typically a conservative assumption, e.g.: “no difference in outcome between the groups”
- ▶ $RR = 1$ or $RD = 0$
- ▶ This is called a **null hypothesis**, H_0

Computing a statistical test

- ▶ Based on the **central limit theorem**:

▶

$$Z_{\text{obs}} = \frac{\hat{RR} - 1}{\text{s.e.}(RR)} \approx \mathcal{N}(0, 1)$$

▶

$$Z_{\text{obs}} = \frac{\hat{RD} - 0}{\text{s.e.}(RD)} \approx \mathcal{N}(0, 1)$$

- ▶ How far are we from the null in terms of the precision
- ▶ **How far** is quantified by the P -value:
 $P = P \{ Z \text{ is more extreme than } Z_{\text{obs}} | H_0 \text{ is true} \}$

Interpretation of P -values

- ▶ Note **it is not** “the probability that H_0 is true” !
- ▶ No mechanical rules of inference
- ▶ Rough guidelines:
 - ▶ “large” value ($p > 0.1$): consistent with H_0 but not necessarily supporting it,
 - ▶ “small” value ($p < 0.01$): indicates evidence against H_0
 - ▶ “intermediate” value ($p \approx 0.05$): weak evidence against H_0
- ▶ Division of p -values into “significant” or “non-significant” by cut-off of 5% — **must be avoided!**
- ▶ ... remember that the 5% is an arbitrary number taken out of thin air.

Confidence interval (CI)


- ▶ Range of values of the parameter compatible with the observed data — the range of null values that will give a P -value larger than 5% ($1 - \text{confidence level}$)
- ▶ Specified at certain **confidence level**, commonly 95% (also 90% and 99% used)
- ▶ The probability that the random interval covers the true parameter value equals the confidence level (e.g. 95%).
- ▶ The probability that the parameter value is in the interval is confidence level (e.g. 95%).

Inference (inference)

48 / 149

Long-term behaviour of CI

Variability of 95% CI under hypothetical repetitions of similar study, when true rate ratio is RR.




In the long run 95% of these intervals would cover the true value but 5% would not.

Inference (inference)

49 / 149

Long-term behaviour of CI

Variability of 95% CI under hypothetical repetitions of similar study, when true rate ratio is RR.



In the long run 95% of these intervals would cover the true value but 5% would not.

Inference (inference)

49 / 149

Interpretation of CI


- ▶ Confidence intervals gives **quantitative** information on the parameter and on statistical uncertainty about its value
- ▶ narrow CI about H_0 value → results give support to H_0
- ▶ narrow CI about non- H_0 value → results give support to an alternative
- ▶ wide CI about H_0 value → results inconclusive
- ▶ wide CI about non- H_0 value → results inconclusive
- ▶ **width** of the interval determines the precision
- ▶ **location** of the interval determines relevance

Inference (inference)

50/ 149

Confidence interval and P -value

95 % CIs of rate difference δ and P values for $H_0 : \delta = 0$ in different studies.



- ▶ Which ones are significant?
- ▶ Which ones are informative?

Inference (inference)

51/ 149

Recommendations

Sterne and Davey Smith: Sifting the evidence – what’s wrong with significance tests? *BMJ* 2001; **322**: 226-231.

“Suggested guidelines for the reporting of results of statistical analyses in medical journals”

1. The description of differences as statistically significant is not acceptable.
2. Confidence intervals (CI) for the main results should always be included, but 90% rather than 95% levels should be used.

Inference (inference)

52/ 149

Recommendations

3. CIs should not be used as a surrogate means of examining significance at the conventional 5% level.
4. Interpretation of CIs should focus on the implications (clinical importance) of the range of values in the interval.
5. In observational studies it should be remembered that considerations of confounding and bias are at least as important as the issues discussed in this paper.

Analysis

Bendix Carstensen & Esa Läärä

Nordic Summerschool of
Cancer Epidemiology
Danish Cancer Society / NCU, August 2019 / January 2020

<http://BendixCarstensen.com/NSCE/2019>

analysis

Crude analysis

- ▶ Single incidence rate
- ▶ Rate ratio in cohort study
- ▶ Rate difference in cohort study
- ▶ Rate ratio in case-control study
- ▶ Analysis of proportions
- ▶ Extensions and remarks

Single incidence rate

- ▶ **Model:** Events occur with constant rate λ .
- ▶ **Parameter** of interest:

$$\lambda = \text{true rate in target population}$$

- ▶ **Estimator:** $\hat{\lambda} = R$, the empirical rate in a “representative sample” from the population:

$$R = \frac{D}{Y} = \frac{\text{no. of cases}}{\text{person-time}}$$

- ▶ Standard error of rate: $SE(R) = R/\sqrt{D}$.

Analysis (analysis)

55/ 149

Example using R

Poisson likelihood for one rate, based on 14 events in 843.6 PY:

```
> library( Epi )
> D <- 14 ; Y <- 843.6
> m1 <- glm( D ~ 1, offset=log(Y/1000), family=poisson)
> ci.exp( m1 )
```

```
              exp(Est.)    2.5%    97.5%
(Intercept) 16.59554 9.82875 28.02107
```

But really both D and Y are outcomes (random variables)

```
> mm <- glm( cbind(D,Y/1000) ~ 1, family=poisreg )
> ci.exp( mm )
```

```
              exp(Est.)    2.5%    97.5%
(Intercept) 16.59554 9.82875 28.02107
```

Analysis (analysis)

56/ 149

Rate ratio in cohort study

Question: What is the rate ratio of cancer in the exposed as compared to the unexposed group?

Model Cancer incidence rates constant in both groups, values λ_1, λ_0

Parameter of interest is ratio of theoretical rates:

$$\rho = \frac{\lambda_1}{\lambda_0} = \frac{\text{rate among exposed}}{\text{rate among unexposed}}$$

Null hypothesis $H_0 : \rho = 1$: exposure has no effect.

Analysis (analysis)

57/ 149

Rate difference in cohort study

Question: What is the rate difference of cancer in the exposed as compared to the unexposed group?

Model Cancer incidence rates constant in both groups, values λ_1, λ_0

Parameter of interest is difference between theoretical rates:

$$\delta = \lambda_1 - \lambda_0 = \text{rate among exposed} - \text{rate among unexposed}$$

Null hypothesis $H_0 : \delta = 0$: exposure has no effect.

Analysis (analysis)

58/ 149

RR example using R

Poisson likelihood, two rates, or one rate and RR:

```
> D <- c(14,28) ; Y <- c(843.6,632.3) ; gg <- factor(0:1)
> m2 <- glm( cbind(D,Y/1000) ~ gg, family=poisreg )
> ci.exp( m2 )
```

```
              exp(Est.)      2.5%      97.5%
(Intercept) 16.595543  9.828750 28.021066
gg1          2.668354  1.404825  5.068325
```

```
> m3 <- glm( cbind(D,Y/1000) ~ gg - 1, family=poisreg )
> ci.exp( m3 )
```

```
              exp(Est.)      2.5%      97.5%
gg0  16.59554  9.82875 28.02107
gg1  44.28278 30.57545 64.13525
```

Analysis (analysis)

59/ 149

RD example using R

Poisson likelihood, two rates, or one rate and RD:

```
> a2 <- glm( cbind(D,Y/1000) ~ gg, family=poisreg(link='identity') )
> ci.exp( m2, Exp=FALSE )
```

```
              Estimate      2.5%      97.5%
(Intercept) 2.8091342 2.2853118 3.332957
gg1          0.9814617 0.3399129 1.623010
```

```
> a3 <- glm( cbind(D,Y/1000) ~ gg - 1, family=poisreg(link='identity') )
> ci.exp( m3, Exp=FALSE )
```

```
              Estimate      2.5%      97.5%
gg0  2.809134 2.285312 3.332957
gg1  3.790596 3.420197 4.160994
```

You do it (**both** RR and RD):

What is the interpretation of the parameters?

Analysis (analysis)

60/ 149

Analysis of proportions

- ▶ Suppose we have cohort data with a **fixed risk period**, i.e. all subjects are followed over the same period and therefore has the same length, as well as no losses to follow-up (no censoring).
- ▶ In this setting the **risk**, π , of the disease over the risk period is estimated by simple
- ▶ **incidence proportion** (often called "**cumulative incidence**" or even "**cumulative risk**")

Analysis of proportions

Theoretical proportion: probability, π , that a random persons becomes a case in the period.

$$\begin{aligned}\widehat{\pi} &= p = \frac{x}{n} \\ &= \frac{\text{number of new cases during period}}{\text{size of population at start}}\end{aligned}$$

Analysis of proportions

Theoretical prevalence: probability, p , that a randomly chosen person in the population is a case.

Analogously, empirical **prevalence** (proportion) at a certain point of time t :

$$\widehat{p} = \frac{\text{no. of prevalent cases at } t}{\text{total population size at } t} = \frac{x}{n}$$

Analysis of proportions

- ▶ Proportions (unlike rates) are dimensionless quantities ranging from 0 to 1
- ▶ Analysis of proportions based on **binomial distribution**
- ▶ Standard error for an estimated proportion:

$$SE(p) = \sqrt{\frac{p(1-p)}{n}} = p \times \sqrt{\frac{(1-p)}{x}}$$

- ▶ Depends also inversely on x !
- ▶ ... but not a good approximation...

Analysis (analysis)

64/ 149

Analysis of proportions

- ▶ CI : $p \pm 2 \times SE(p)$ are within $[0; 1]$ if $x > 4/(1 + 4/n)$
- ▶ This is always true if $x > 3$ (if $x > 2$ for $n < 12$)
- ▶ — but the approximation is not good for $x < 10$

```
> ci <- function(x,n) round(cbind( x, n, p=p<-x/n, lo=p-2*sqrt(p*(1-p)/n),
+                               hi=p+2*sqrt(p*(1-p)/n) ),4)
> rbind(ci(3,11:13),ci(2,3:5),ci(1,1:2))
```

```
      x  n    p    lo    hi
[1,] 3 11 0.2727 0.0042 0.5413
[2,] 3 12 0.2500 0.0000 0.5000
[3,] 3 13 0.2308 -0.0029 0.4645
[4,] 2  3 0.6667 0.1223 1.2110
[5,] 2  4 0.5000 0.0000 1.0000
[6,] 2  5 0.4000 -0.0382 0.8382
[7,] 1  1 1.0000 1.0000 1.0000
[8,] 1  2 0.5000 -0.2071 1.2071
```

Analysis (analysis)

65/ 149

Analysis of proportions

- ▶ Use confidence limits based on symmetric (normal) $\log(\text{OR})$:
- ▶ Compute error factor: $EF = \exp(1.96/\sqrt{np(1-p)})$
- ▶ then use to compute confidence interval:

$$p/(p + (1-p) \times EF)$$

- ▶ Observed $x = 4$ out of $n = 25$: $\hat{p} = 4/25 = 0.16$
- ▶ Naive CI: $0.16 \pm 1.96 \times \sqrt{0.16 \times 0.84/25} = [0.016; 0.304]$
- ▶ Better: $EF = \exp(1.96/\sqrt{25 \times 0.16 \times 0.84}) = 2.913$

$$CI : 0.16/(0.16 + (0.84 \times 2.913)) = [0.061; 0.357]$$

Analysis (analysis)

66/ 149

Analysis of proportions by glm

- ▶ Default is to model $\text{logit}(p) = \log(p/(1 - p))$, log-odds
- ▶ Using `ci.exp` gives odds (ω):

$$\omega = p/(1 - p) \quad \Leftrightarrow \quad p = \omega/(1 + \omega)$$

```
> x <- 4 ; n <- 25
> p0 <- glm( cbind( x, n-x ) ~ 1, family=binomial )
> ( odds <- ci.exp( p0 ) )

              exp(Est.)      2.5%      97.5%
(Intercept) 0.1904762 0.06538417 0.5548924

> odds/(odds+1)

              exp(Est.)      2.5%      97.5%
(Intercept) 0.16 0.06137145 0.3568687
```

Analysis (analysis)

67/ 149

Analysis of proportions by glm

Also possible to model $\log(p)$, log-probability, by changing the link function:

```
> x <- 4 ; n <- 25
> pl <- glm( cbind( x, n-x ) ~ 1, family=binomial(link="log" ) )
> ci.exp( pl )

              exp(Est.)      2.5%      97.5%
(Intercept) 0.16 0.06517056 0.3928154

> odds/(odds+1)

              exp(Est.)      2.5%      97.5%
(Intercept) 0.16 0.06137145 0.3568687
```

We see that the estimated probability is the same but the confidence limits are slightly different.

Analysis (analysis)

68/ 149

Rate ratio in case-control study

Parameter of interest: $\rho = \lambda_1/\lambda_0$

— same as in cohort study.

Case-control design:

- ▶ **incident cases** occurring during a given period in the source population are collected
- ▶ **controls** are obtained by *incidence density sampling* from those at risk in the study base
- ▶ **exposure** is ascertained in cases and chosen controls.

Analysis (analysis)

69/ 149

Rate ratio in case-control study

Summarized data on outcome:

Exposure	Cases	Controls
yes	D_1	C_1
no	D_0	C_0

- ▶ Can we directly estimate the rates λ_0 and λ_1 from this?
- ▶ — and the ratio of these?
- ▶ NO and YES (respectively)
- ▶ Rates are **not** estimable from a case-control design

Analysis (analysis)

70/ 149

Rate ratio in case-control study

- ▶ If controls are representative of the person- years in the population, their division into exposure groups estimates the exposure distribution of the person-years:

$$C_1/C_0 \approx Y_1/Y_0$$

- ▶ Hence, we can estimate the RR by the OR:

$$\widehat{RR} = OR = \frac{D_1/Y_1}{D_0/Y_0} = \frac{D_1/D_0}{Y_1/Y_0} \approx \frac{D_1/D_0}{C_1/C_0} = \frac{D_1/C_1}{D_0/C_0}$$

⇒ RR estimated by the ratio of the case-control ratios (D/C)

- ▶ ... but of course there is a penalty to pay...

Analysis (analysis)

71/ 149

Rate ratio from case-control study

Standard error for $\log(OR)$, 95% error factor and approximate CI for OR:

$$\begin{aligned} SE(\log(OR)) &= \sqrt{\frac{1}{D_1} + \frac{1}{D_0} + \frac{1}{C_1} + \frac{1}{C_0}} \\ EF &= \exp\left(1.96 \times SE(\log(OR))\right) \\ CI &= [OR/EF, OR \times EF] \end{aligned}$$

NB. Random error again depends inversely on numbers of cases **and** controls — the penalty, in the two exposure groups.

Analysis (analysis)

72/ 149

Example: mobile phone use and brain cancer

(Inskip *et al.* NEJM 2001; 344: 79-86).

Daily use	Cases	Controls
≥ 15 min	35	51
no use	637	625

The RR associated with use of mobile phone longer than 15 min (vs. none) is estimated by the OR:

$$\text{OR} = \frac{35/51}{637/625} = 0.67$$

Analysis (analysis)

73/ 149

Example: mobile phone use and brain cancer

SE for $\log(\text{OR})$, 95% error factor and approximate CI for OR:

$$\text{SE}(\log(\text{OR})) = \sqrt{\frac{1}{35} + \frac{1}{637} + \frac{1}{51} + \frac{1}{625}} = 0.2266$$

$$\text{EF} = \exp(1.96 \times 0.2266) = 1.45$$

$$\text{CI} = [0.67/1.45, 0.67 \times 1.45] = [0.43, 1.05]$$

N.B. model-adjusted estimate (with 95% CI):

$$\text{OR} = 0.6[0.3, 1.0]$$

Analysis (analysis)

74/ 149

OR from binomial model

```
> Ca <- c(638,35); Co <- c(625,51); Ex <- factor(c("None", ">15"), levels=c("None",  
> data.frame( Ca, Co, Ex )
```

```
  Ca Co  Ex  
1 638 625 None  
2  35  51 >15
```

```
> mf <- glm( cbind(Ca,Co) ~ Ex, family=binomial )  
> ci.exp( mf )
```

```
                exp(Est.)      2.5%      97.5%  
(Intercept) 1.0208000 0.9141876 1.139845  
Ex>15       0.6722909 0.4311979 1.048185
```

- ▶ Intercept is meaningless; only exposure estimate is relevant
- ▶ The parameter in the model is $\log(\text{OR})$, so using `ci.exp` gives us the estimated OR — same as in the hand-calculation above.
- ▶ This is called **logistic regression**

Analysis (analysis)

75/ 149

Extensions and remarks

- ▶ This extends to crude analyses of exposure variables with several categories when each exposure category is separately compared to a reference group
- ▶ Evaluation of possible monotone trend in the parameter over increasing levels of exposure: estimation of regression slope
- ▶ Crude analysis is insufficient in observational studies:
- ▶ control of confounding needed

Short recap

Bendix Carstensen & Esa Läärä

Nordic Summerschool of
Cancer Epidemiology
Danish Cancer Society / NCU, August 2019 / January 2020

<http://BendixCarstensen.com/NSCE/2019>

recap

Rates

- ▶ dimension time^{-1}
- ▶ estimated as $\hat{\lambda} = D/Y$
- ▶ confidence interval for λ :
 - ▶ multiplicative $\lambda \times \text{erf}$
 - ▶ additive $\lambda \pm \text{EM}$

Practical model for rates

```
> library( Epi )
> D <- 14 ; Y <- 843.6/1000 ; D/Y
[1] 16.59554
> m0 <- glm( D ~ 1, offset=log(Y), family=poisson )
> ci.exp( m0 )
              exp(Est.)    2.5%    97.5%
(Intercept) 16.59554  9.82875 28.02107
```

Better way:

```
> mm <- glm( cbind(D,Y) ~ 1, family=poisreg )
> ci.exp( mm )
              exp(Est.)    2.5%    97.5%
(Intercept) 16.59554  9.82875 28.02107
```

Short recap (recap)

78 / 149

Allows error factor and margin too:

```
> mm <- glm( cbind(D,Y) ~ 1, family=poisreg )
> ci.exp( mm )
              exp(Est.)    2.5%    97.5%
(Intercept) 16.59554  9.82875 28.02107
```

With error margin (conf.int. on rate-scale)

```
> ma <- glm( cbind(D,Y) ~ 1, family=poisreg(link="identity") )
> ci.exp( ma, Exp=FALSE )
              Estimate    2.5%    97.5%
(Intercept) 16.59554  7.902426 25.28866
```

Short recap (recap)

79 / 149

Rate ratio and rate difference

```
> D <- c(14,28) ; Y <- c(843.6,632.3)/1000 ; gg <- factor(0:1)
> mr <- glm( cbind(D,Y) ~ gg, family=poisreg )
> ci.exp( mr )
              exp(Est.)    2.5%    97.5%
(Intercept) 16.595543  9.828750 28.021066
gg1         2.668354  1.404825  5.068325
> mR <- glm( cbind(D,Y) ~ gg-1, family=poisreg )
> ci.exp( mR )
              exp(Est.)    2.5%    97.5%
gg0 16.59554  9.82875 28.02107
gg1 44.28278 30.57545 64.13525
```

Short recap (recap)

80 / 149

Rate ratio and rate difference

```
> ma <- glm( cbind(D,Y) ~ gg, family=poisreg(link="identity") )
> ci.exp( ma, Exp=FALSE )

              Estimate      2.5%      97.5%
(Intercept) 16.59554  7.902426 25.28866
gg1         27.68723  9.123703 46.25077

> mA <- glm( cbind(D,Y) ~ gg-1, family=poisreg(link="identity") )
> ci.exp( mA, Exp=FALSE )

              Estimate      2.5%      97.5%
gg0 16.59554  7.902426 25.28866
gg1 44.28278 27.880508 60.68505
```

Short recap (recap)

81/ 149

Models

- ▶ Probability model: Data generator, model to data
- ▶ Statistical analysis: From data to model (parameters)
- ▶ Maximum likelihood is the basis for parameter estimation
- ▶ But only for given model
- ▶ Normal approximation provides confidence intervals
- ▶ — either for log-rates, rates, RR, RD, OR
- ▶ Beware of P -values

Short recap (recap)

82/ 149

Stratified analysis

Bendix Carstensen & Esa Läärä

Nordic Summerschool of
Cancer Epidemiology
Danish Cancer Society / NCU, August 2019 / January 2020

Stratified analysis

- ▶ Shortcomings of crude analysis
- ▶ Effect modification
- ▶ Confounding
- ▶ Steps of stratified analysis
- ▶ Estimation of rate ratio
- ▶ Matched case-control study

Shortcomings of crude analysis

- ▶ the rate ratio for the risk factor of interest is not constant, but varies by other determinants of the disease
- ⇐ heterogeneity of the comparative parameter or **effect modification**
- ▶ the exposure groups are not comparable w.r.t. other determinants of disease
- ⇒ bias in comparison or **confounding**
- ⇐ exposure varies across other determinants

Models for outcome with effects of

- ▶ primary variable (“exposure”)
- ▶ secondary variable (“stratum”)
- ▶ **effect modification** is the interaction model
exposure × stratum
exposure with **different** effects across strata
- ▶ **confounding** is the main-effects model
exposure + stratum exposure with **same** effect across strata

Handling for effect modification and confounding

- ▶ **Stratification** of data
by potentially modifying and/or confounding factor(s)
& use of **adjusted** estimators
- ▶ Conceptually simpler,
and technically less demanding approach is
regression modeling
- ▶ Regression modeling is feasible because we have computers
- ▶ ... adjustment estimators are left-overs from teachers taught
before the advent of computers (e.g. BxC & EL...)

Stratified analysis (strat)

86 / 149

Effect modification

Incidence rates (per 10^5 PY) of lung cancer by occupational asbestos exposure and smoking:

Asbestos	Smokers	Non-smokers
exposed	600	60
unexposed	120	12
Rate ratio	5	5
Rate difference	480	48

Is the effect of asbestos exposure the same or different in smokers than in non-smokers?

Stratified analysis (strat)

87 / 149

Effect modification (cont'd)

Depends how the effect is measured:

- ▶ Rate ratio: constant or **homogeneous**
- ▶ Rate difference: **heterogeneous**:
The value of rate difference is modified by smoking.

Smoking is thus an **effect modifier** of asbestos exposure on the absolute scale (rates) but **not** on the relative scale (log-rates)

Stratified analysis (strat)

88 / 149

Incidence of CHD (per 10³ PY) by risk factor E and age:

Factor E	Young	Old
exposed	4	9
unexposed	1	6
rate ratio	4	1.5
rate difference	3	3

- ▶ Rate ratio modified by age
- ▶ Rate difference not modified.
- ▶ There is no such thing as interaction (effect modification) without reference to the **scale** of the effect (e.g. additive or multiplicative)

Stratified analysis (strat)

89/ 149

Handling effect modification

- ▶ In real examples, comparative parameters are more or less heterogeneous across categories of other determinants of disease
- ▶ This is termed **interaction** or **effect modification**
- ▶ The effect of X depend on the level of Z
- ▶ The effect of X cannot be described by a single number,
- ▶ ... it is a function of Z

Stratified analysis (strat)

90/ 149

Actual example

Age-specific CHD mortality rates (per 10⁴ PY) and numbers of cases (D) among British male doctors by cigarette smoking, rate differences (RD) and rate ratios (RR) (Doll and Hill, 1966).

Age (y)	Smokers		Non-smokers		RD	RR
	rate	D	rate	D		
35-44	6.1	32	1.1	2	5	5.7
45-54	24	104	11	12	13	2.1
55-64	72	206	49	28	23	1.5
65-74	147	186	108	28	39	1.4
75-84	192	102	212	31	-20	0.9
Total	44	630	26	101	18	1.7

Stratified analysis (strat)

91/ 149

CHD and smoking

Both comparative parameters appear heterogeneous:

- ▶ RD increases by age (at least up to 75 y)
- ▶ RR decreases by age

No single-parameter (common rate ratio or rate difference) comparison captures adequately the joint pattern of rates.

Evaluation of modification

- ▶ Modification or its absence is an inherent property of the phenomenon:
- ▶ cannot be removed or “adjusted” for
- ▶ — it depends on the **scale** on which it is measured
- ▶ Before looking for effect-modification:
 - ▶ what **scale** are we using for description of effects
 - ▶ how will we **report** the modified effects (the interaction)

Evaluation of modification (cont'd)

- ▶ statistical tests for heterogeneity insensitive and rarely helpful
- ▶ ⇒ tempting to assume “no essential modification”:
- + simpler analysis and result presentation,
- misleading if essential modification present.

CHD and smoking example with R I

```
> library( Epi )
> R <- c(6.1, 24, 72,147,192, 1.1,11,49,108,212)
> D <- c( 32,104,206,186,102, 2 ,12,28, 28, 31)
> Y <- D/R # risk time in units of 10^4 PY
> smk <- factor( rep(1:2,each=5), labels=c("Smoke","non-Sm") )
> age <- factor( rep(seq(35,75,10),2) )
> data.frame(D,Y,age,smk)
```

CHD and smoking example with R II

	D	Y	age	smk
1	32	5.2459016	35	Smoke
2	104	4.3333333	45	Smoke
3	206	2.8611111	55	Smoke
4	186	1.2653061	65	Smoke
5	102	0.5312500	75	Smoke
6	2	1.8181818	35	non-Sm
7	12	1.0909091	45	non-Sm
8	28	0.5714286	55	non-Sm
9	28	0.2592593	65	non-Sm
10	31	0.1462264	75	non-Sm

```
> ma <- glm( cbind(D,Y) ~ age + smk, family=poisreg )
> mi <- update( ma, . ~ . + age:smk ) # add the interaction
> anova( ma, mi, test="Chisq" )
```

CHD and smoking example with R III

Analysis of Deviance Table

```
Model 1: cbind(D, Y) ~ age + smk
Model 2: cbind(D, Y) ~ age + smk + age:smk
  Resid. Df Resid. Dev Df Deviance Pr(>Chi)
1         4      11.993
2         0         0.000  4   11.993  0.0174
```

```
> aa <- glm( cbind(D,Y) ~ age + smk, family=poisreg(link='identity') )
> ai <- update( ma, . ~ . + age:smk ) # add the interaction
> anova( aa, ai, test="Chisq" )
```

Analysis of Deviance Table

```
Model 1: cbind(D, Y) ~ age + smk
Model 2: cbind(D, Y) ~ age + smk + age:smk
  Resid. Df Resid. Dev Df Deviance Pr(>Chi)
1         4       7.7434
2         0         0.0000  4   7.7434  0.1014
```

Confounding - operation example

Observational clinical study with comparison of success of treatment between two types of operation for treating renal calculi:

- ▶ OS: open surgery (invasive)
- ▶ PN: percutaneous nephrolithotomy (non-invasive)

Treatment	Pts	Op. OK	% OK	%-diff.
OS	350	273	78	
PN	350	290	83	+5

PN appears more successful than OS?

Stratified analysis (strat)

98 / 149

Operation example

Results stratified by initial diameter size of the stone:

Size	Treatment	Pts	Op. OK	% OK	%-diff.
< 2 cm:	OS	87	81	93	
	PN	270	235	87	-6
≥ 2 cm:	OS	263	192	73	
	PN	80	55	69	-4

OS seems more succesful in both subgroups.

Is there a paradox here?

Stratified analysis (strat)

99 / 149

Operation example

- ▶ Treatment groups are not comparable w.r.t. initial size.
- ▶ Size of the stone (SS) is a **confounder** of the association between operation type and success:
 - 1 a determinant of outcome (success), based on external knowledge,
 - 2 statistically associated with operation type in the study population,
 - 3 not causally affected by operation type.

Stratified analysis (strat)

100 / 149

Operation example

- ▶ Instance of “confounding by indication”:
 - patient status affects choice of treatment,
 - ⇒ bias in comparing treatments.
- ▶ This bias is best avoided in planning:
 - randomized allocation of treatment.

Grey hair and cancer incidence

Age	Gray hair	Cases	P-years ×1000	Rate /1000 y	RR
Total	yes	66	25	2.64	2.2
	no	30	25	1.20	
Young	yes	6	10	0.60	1.09
	no	11	20	0.55	
Old	yes	60	15	4.0	1.05
	no	19	5	3.8	

Observed crude association nearly vanishes after controlling for age.

Means for control of confounding

Design:

- ▶ Randomization
- ▶ Restriction
- ▶ Matching

Means for control of confounding (cont'd)

Analysis:

- ▶ Stratification
- ▶ Regression modeling

Only randomization can remove confounding due to **unmeasured** factors.

Other methods provide partial removal, but **residual** confounding may remain.

Steps of stratified analysis

- ▶ Stratify by levels of the potential confounding/modifying factor(s)
- ▶ Compute stratum-specific estimates of the effect parameter (e.g. RR or RD)
- ▶ Evaluate similarity of the stratum-specific estimates by “eye-balling” or test of heterogeneity.

Steps of stratified analysis (cont.)

- ▶ If the parameter is judged to be homogeneous enough, calculate an adjusted summary estimate.
- ▶ If effect modification is judged to be present:
 - ▶ report stratum-specific estimates with CIs,
 - ▶ if desired, calculate an adjusted summary estimate by appropriate standardization — (formally meaningless).

Estimation of rate ratio

- ▶ Suppose that the rate ratio RR is sufficiently homogeneous across strata (no modification), but confounding is present.
- ▶ Crude RR estimator is biased.
- ▶ **Adjusted summary estimator**, controlling for confounding, must be used.
- ▶ These estimators are **weighted** averages of stratum-specific estimators.

Adjusted summary estimators

Different weighting methods:

- ▶ maximum likelihood (ML)
- ▶ weighted least squares (WLS)
- ▶ Mantel-Haenszel (MH) weights
- ▶ (direct) standardization by external standard population (CMF)
- ▶ standardized morbidity ratio (SMR)

Preferred method in analysis: ML Useful method in simple descriptive: CMF / SMR

Gray hair & cancer

```
> D <- c(6,11,60,19)
> Y <- c(10,20,15,5)
> age <- factor( c("Young","Young","Old","Old") )
> hair <- factor( c("Gray","Col","Gray","Col") )
> data.frame( D, Y, age, hair )
```

```
  D  Y  age hair
1  6 10 Young Gray
2 11 20 Young Col
3 60 15  Old Gray
4 19  5  Old Col
```


Gray hair & cancer

Crude and adjusted risk estimate by Poisson model:

```
> library( Epi )
> ci.exp( glm( cbind(D,Y) ~ hair          , family=poisreg ) )

              exp(Est.)      2.5%      97.5%
(Intercept)      1.2 0.8390232 1.716281
hairGray         2.2 1.4288756 3.387279

> ci.exp( glm( cbind(D,Y) ~ hair + age, family=poisreg ) )

              exp(Est.)      2.5%      97.5%
(Intercept) 3.7782269 2.49962653 5.7108526
hairGray    1.0606186 0.67013527 1.6786339
ageYoung    0.1470116 0.08418635 0.2567211
```

Stratified analysis (strat)

110/ 149

Case-control study of Alcohol and oesophageal cancer

- ▶ Tuyns *et al.* 1977, see Breslow & Day 1980,
- ▶ 205 incident cases,
- ▶ 770 unmatched population controls,
- ▶ Risk factor: daily consumption of alcohol.
- ▶ Crude summary:

Exposure	Cases	Controls	OR
≥ 80 g/d			
yes	96	109	5.64
no	104	666	

Stratified analysis (strat)

111/ 149

Crude analysis of CC-data

```
> Ca <- c( 96,104)
> Co <- c(109,666)
> Ex <- factor(c(">80","<80"))
> data.frame( Ca, Co, Ex )

   Ca Co Ex
1  96 109 >80
2 104 666 <80

> m0 <- glm( cbind(Ca,Co) ~ Ex, family=binomial )
> round( ci.exp( m0 ), 2 )

              exp(Est.) 2.5% 97.5%
(Intercept)      0.16 0.13 0.19
Ex>80            5.64 4.00 7.95
```

The odds-ratio of oesophageal cancer, comparing high vs. low alcohol consumption is 5.64(4.00; 7.95)

Stratified analysis (strat)

112/ 149

Stratification by age

Age	Exposure	Cases	Controls	EOR
	≥ 80 g/d			
25-34	yes	1	9	∞
	no	0	106	
35-44	yes	4	26	5.05
	no	5	164	
45-54	yes	25	29	5.67
	no	21	138	
55-64	yes	42	27	6.36
	no	34	139	
65-74	yes	19	18	2.58
	no	36	88	
75-84	yes	5	0	∞
	no	8	31	

NB! Selection of controls: inefficient study
Should have employed stratified sampling by age.

Stratified analysis (strat)

113/ 149

Stratified analysis

```
> ca <- c( 1, 0, 4, 5, 25, 21, 42, 34, 19, 36, 5, 8 )
> co <- c(9, 106, 26, 164, 29, 138, 27, 139, 18, 88, 0, 31)
> alc <- rep( c(">80", "<80"), 6 )
> age <- factor( rep( seq(25,75,10), each=2 ) )
> data.frame( ca, co, alc, age )
```

```
   ca  co alc age
1    1   9 >80 25
2    0 106 <80 25
3    4  26 >80 35
4    5 164 <80 35
5   25  29 >80 45
6   21 138 <80 45
7   42  27 >80 55
8   34 139 <80 55
9   19  18 >80 65
10  36  88 <80 65
11   5   0 >80 75
12   8  31 <80 75
```

Stratified analysis (strat)

114/ 149

Stratified analysis

The “age:” operator produces a separate aIc-OR for each age class (in the absence of a main effect of aIc):

```
> mi <- glm( cbind(ca,co) ~ age + age:alc, family=binomial )
> round( ci.exp( mi ), 3 )
```

```
              exp(Est.)  2.5%  97.5%
(Intercept) 0.000000e+00 0.000    Inf
age35       2.345328e+10 0.000    Inf
age45       1.170624e+11 0.000    Inf
age55       1.881661e+11 0.000    Inf
age65       3.147003e+11 0.000    Inf
age75       1.985206e+11 0.000    Inf
age25:alc>80 8.547416e+10 0.000    Inf
age35:alc>80 5.046000e+00 1.272 20.025
age45:alc>80 5.665000e+00 2.799 11.464
age55:alc>80 6.359000e+00 3.449 11.726
age65:alc>80 2.580000e+00 1.216  5.475
age75:alc>80 1.755246e+11 0.000    Inf
```

Stratified analysis (strat)

115/ 149

Stratified analysis

... only the relevant parameters:

```
> round( ci.exp( mi, subset="alc" ), 3 )
              exp(Est.)  2.5%  97.5%
age25:alc>80 8.547416e+10 0.000   Inf
age35:alc>80 5.046000e+00 1.272 20.025
age45:alc>80 5.665000e+00 2.799 11.464
age55:alc>80 6.359000e+00 3.449 11.726
age65:alc>80 2.580000e+00 1.216  5.475
age75:alc>80 1.755246e+11 0.000   Inf
```

- ▶ The age-specific ORs are quite variable
- ▶ Random error in some of them apparently large
- ▶ No clear pattern in the interaction

Stratified analysis (strat)

116/ 149

Oesophageal cancer CC — effect modification?

```
> ma <- glm( cbind(ca,co) ~ age + alc, family=binomial )
> anova( mi, ma, test="Chisq" )
```

Analysis of Deviance Table

```
Model 1: cbind(ca, co) ~ age + age:alc
Model 2: cbind(ca, co) ~ age + alc
  Resid. Df Resid. Dev Df Deviance Pr(>Chi)
1         0      0.000
2         5     11.041 -5  -11.041  0.05057
```

- ▶ Some evidence against homogeneity, but no clear pattern in the interaction (effect modification)
- ▶ Extract a common effect from the reduced model

Stratified analysis (strat)

117/ 149

Oesophageal cancer CC — linear effect modification

```
> ml <- glm( cbind(ca,co) ~ age + alc*as.integer(age), family=binomial )
> round( ci.exp( ml, subset="alc" ), 3 )
```

```
              exp(Est.)  2.5%  97.5%
alc>80          8.584 1.961 37.579
alc>80:as.integer(age) 0.883 0.609  1.279
```

```
> ma <- glm( cbind(ca,co) ~ age + alc, family=binomial )
> anova( mi, ml, ma, test="Chisq" )[1:3,1:5]
```

```
  Resid. Df Resid. Dev Df Deviance Pr(>Chi)
1         0      0.000
2         4     10.609 -4  -10.6093  0.03132
3         5     11.041 -1   -0.4319  0.51107
```

Evidence against linear interaction (OR decreasing by age)

Stratified analysis (strat)

118/ 149

Oesophageal cancer CC — effect modification?

```
> mn <- glm( cbind(ca,co) ~ alc , family=binomial )
> round( ci.exp( mn, subset="alc" ), 2 )

      exp(Est.) 2.5% 97.5%
alc>80      5.64   4   7.95

> ma <- glm( cbind(ca,co) ~ age + alc, family=binomial )
> round( ci.exp( ma, subset="alc" ), 2 )

      exp(Est.) 2.5% 97.5%
alc>80      5.31 3.66  7.7
```

- ▶ No clear interaction (effect modification) detected
- ▶ Crude OR: 5.64(4.00; 7.95)
- ▶ Adjusted OR: 5.31(3.66; 7.70)
- ▶ **Note:** No test for confounding exists.

Stratified analysis (strat)

119 / 149

Regression models

Bendix Carstensen & Esa Läärä

Nordic Summerschool of
Cancer Epidemiology
Danish Cancer Society / NCU, August 2019 / January 2020

<http://BendixCarstensen.com/NSCE/2019>

regress

Regression modeling

- ▶ Limitations of stratified analysis
- ▶ Log-linear model for rates
- ▶ Additive model for rates
- ▶ Model fitting
- ▶ Problems in modeling

Regression models (regress)

120 / 149

Limitations of stratified analysis

- ▶ Multiple stratification:
 - ▶ many strata with sparse data
 - ▶ loss of precision
- ▶ Continuous risk factors must be categorized
 - ▶ loss of precision
 - ▶ arbitrary (unreasonable) assumptions about effect shape
- ▶ More than 2 exposure categories:
 - ▶ Pairwise comparisons give inconsistent results
 - ▶ (non)Linear trends not easily estimated

Limitations

- ▶ Joint effects of several risk factors difficult to quantify
- ▶ Matched case-control studies:
difficult to allow for confounders & modifiers not matched on.

These limitations may be overcome to some extent by regression modeling.

Key concept: **statistical model**

Log-linear model for rates

Assume that the theoretical rate λ depends on **explanatory variables** or **regressors** X, Z (& U, V, \dots) according to a **log-linear** model

$$\log(\lambda(X, Z, \dots)) = \alpha + \beta X + \gamma Z + \dots$$

Equivalent expression, **multiplicative model**:

$$\begin{aligned}\lambda(X, Z, \dots) &= \exp(\alpha + \beta X + \gamma Z + \dots) \\ &= \lambda_0 \rho^X \tau^Z \dots\end{aligned}$$

Log-linear model

Model parameters

$\alpha = \log(\lambda_0) =$ intercept, log-baseline rate λ_0
(i.e. rate when $X = Z = \dots = 0$)

$\beta = \log(\rho) =$ slope,
change in $\log(\lambda)$ for unit change in X ,
adjusting for the effect of Z (& U, V, \dots)

$e^\beta = \rho =$ rate ratio for unit change in X .

No effect modification w.r.t. rate ratios assumed in this model.

Lung cancer incidence, asbestos exposure and smoking

Dichotomous explanatory variables coded:

- ▶ $X =$ asbestos: 1: exposed, 0: unexposed,
- ▶ $Z =$ smoking: 1: smoker, 0: non-smoker

Log-linear model for theoretical rates

$$\log(\lambda(X, Z)) = 2.485 + 1.609X + 2.303Z$$

Log-linear model: Variables

	Rates		Variables			
	Smoke	Non-sm	X		Z	
Asbestos	Smoke	Non-sm	Smoke	Non-sm	Smoke	Non-sm
exposed	600	60	1	1	1	0
unexposed	120	12	0	0	1	0

Note: There will be **4** lines in the dataset, one for each combination of exposure and smoking

Lung cancer, asbestos and smoking

Entering the data:

— note that the data are artificial assuming the no. of PY among asbestos exposed is 1/4 of that among non-exposed

```
> D <- c( 150, 15, 120, 12 ) # cases
> Y <- c( 25, 25, 100, 100 ) / 100 # PY (100,000s)
> asb <- c( 1, 1, 0, 0 ) # Asbestos exposure
> smk <- c( 1, 0, 1, 0 ) # Smoking
> cbind( D, Y, asb, smk )

      D      Y asb smk
[1,] 150 0.25  1  1
[2,]  15 0.25  1  0
[3,] 120 1.00  0  1
[4,]  12 1.00  0  0
```

Regression models (regress)

127 / 149

Lung cancer, asbestos and smoking

- ▶ Regression modeling
- ▶ Multiplicative (default) Poisson model
- ▶ 2 equivalent approaches
 - ▶ D response, $\log(Y)$ offset (mostly used in the literature)
 - ▶ `cbind(D,Y)` response, `family=poisreg`
 - ▶ ...the latter approach also useful for **additive** models

```
> library( Epi )
> mo <- glm( D ~ asb + smk, family=poisson, offset=log(Y) )
> mm <- glm( cbind(D,Y) ~ asb + smk, family=poisreg )
> ma <- glm( cbind(D,Y) ~ asb + smk, family=poisreg(link=identity) )
```

Regression models (regress)

128 / 149

Lung cancer, asbestos and smoking

Summary and extraction of parameters:

```
> summary( mo )

Call:
glm(formula = D ~ asb + smk, family = poisson, offset = log(Y))

Deviance Residuals:
    1      2      3      4 
1.154e-07  0.000e+00  1.032e-07  0.000e+00

Coefficients:
            Estimate Std. Error z value Pr(>|z|)
(Intercept)  2.4849      0.2031  12.23  <2e-16
asb          1.6094      0.1168  13.78  <2e-16
smk          2.3026      0.2018  11.41  <2e-16
```

(Dispersion parameter for poisson family taken to be 1)

```
Null deviance: 4.1274e+02 on 3 degrees of freedom
Residual deviance: 2.3093e-14 on 1 degrees of freedom
```

Regression models (regress)

129 / 149

Summary and extraction of parameters I

```
> ci.exp( mo )

      exp(Est.)      2.5%      97.5%
(Intercept)      12 8.059539 17.867026
asb              5 3.977142  6.285921
smk             10 6.732721 14.852836

> ci.exp( mo, Exp=F )

      Estimate      2.5%      97.5%
(Intercept) 2.484907 2.086856 2.882957
asb         1.609438 1.380563 1.838312
smk         2.302585 1.906979 2.698191

> ci.exp( mm, Exp=F )
```

Summary and extraction of parameters II

```
      Estimate      2.5%      97.5%
(Intercept) 2.484907 2.086856 2.882957
asb         1.609438 1.380563 1.838312
smk         2.302585 1.906979 2.698191
```

Parameters are the same for the two modeling approaches.

Interpretation of parameters I

```
> round( cbind( ci.exp( mm, Exp=F ),
+             ci.exp( mm           ) ), 3 )

      Estimate  2.5% 97.5% exp(Est.)  2.5% 97.5%
(Intercept)   2.485 2.087 2.883      12 8.060 17.867
asb           1.609 1.381 1.838       5 3.977  6.286
smk           2.303 1.907 2.698      10 6.733 14.853
```

$\alpha = 2.485 = \log(12)$, log of baseline rate,

$\beta = 1.609 = \log(5)$, log of rate ratio $\rho = 5$ between exposed and unexposed for asbestos

$\gamma = 2.303 = \log(10)$, log of rate ratio $\tau = 10$ between smokers and non-smokers.

Interpretation of parameters II

Rates for all 4 asbestos/smoking combinations can be recovered from the above formula.

Log-linear model: Estimated rates

Asbestos	Rates		Parameters	
	Smokers	Non-smokers	Smokers	Non-smokers
exposed	600	60	$\alpha + \gamma + \beta$	$\alpha + \beta$
unexposed	120	12	$\alpha + \gamma$	α
Rate ratio	5	5	$\exp(\beta)$	$\exp(\beta)$
Rate difference	480	48	β	β

Log-linear model

Model with effect modification (two regressors only)

$$\log(\lambda(X, Z)) = \alpha + \beta X + \gamma Z + \delta XZ,$$

equivalently

$$\lambda(X, Z) = \exp(\alpha + \beta X + \gamma Z + \delta XZ) = \lambda_0 \rho^X \tau^Z \theta^{XZ}$$

where α is as before, but

β = log-rate ratio ρ for a unit change in X when $Z = 0$,

γ = log-rate ratio τ for a unit change in Z when $X = 0$

Interaction parameter

$\delta = \log(\theta)$, interaction parameter, describing effect modification

For binary X and Z we have

$$\theta = e^{\delta} = \frac{\lambda(1, 1)/\lambda(0, 1)}{\lambda(1, 0)/\lambda(0, 0)},$$

i.e. the ratio of relative risks associated with X between the two categories of Z .

Log-linear model: Estimated rates

Asbestos	Rates		Parameters	
	Smokers	Non-smokers	Smokers	Non-smoker
exposed	600	60	$\alpha + \gamma + \beta + \delta$	$\alpha + \beta$
unexposed	120	12	$\alpha + \gamma$	α
Rate ratio	5	5	$\log(\beta + \delta)$	$\log(\beta)$
Rate difference	480	48	$\beta + \delta$	β

Lung cancer, asbestos and smoking

```
> mi <- glm( cbind(D,Y) ~ asb + smk + I(asb*smk), family=poisreg )
> round( cbind(
+           ci.exp( mi ),
+           rbind(ci.exp( mm ),NA) ), 3 )
```

```

exp(Est.)  2.5%  97.5% exp(Est.)  2.5%  97.5%
(Intercept)      12 6.815 21.130      12 8.060 17.867
asb                5 2.340 10.682        5 3.977  6.286
smk               10 5.524 18.101       10 6.733 14.853
I(asb * smk)      1 0.451  2.217         NA   NA   NA
```

- ▶ No interaction on the multiplicative scale:
- ▶ interaction parameter is 1,
- ▶ asbestos and smoking effects are the unchanged,
- ▶ but SEs are larger because they refer to RRs for levels $X = 0$ and $Z = 0$ respectively and not both levels **jointly**

Additive model for rates

General form with two regressors

$$\lambda(X, Z) = \alpha + \beta X + \gamma Z + \delta XZ$$

$\alpha = \lambda(0, 0)$ is the baseline rate,

$\beta = \lambda(x + 1, 0) - \lambda(x, 0)$, rate difference for unit change in X when $Z = 0$

$\gamma = \lambda(0, z + 1) - \lambda(0, z)$, rate difference for unit change in Z when $X = 0$,

Additive model

δ = interaction parameter.

► For binary X, Z :

$$\delta = [\lambda(1, 1) - \lambda(1, 0)] - [\lambda(0, 1) - \lambda(0, 0)]$$

► If no effect modification present, $\delta = 0$, and

β = rate difference for unit change in X for all values of Z

γ = rate difference for unit change in Z for all values of X ,

Example: Additive model

```
> mai <- glm( cbind(D,Y) ~ asb + smk + asb*smk, family=poisreg(link=identity) )
> round( ci.exp( mai, Exp=FALSE, pval=TRUE ), 4 )
```

	Estimate	2.5%	97.5%	P
(Intercept)	12	5.2105	18.7895	0.0005
asb	48	16.8865	79.1135	0.0025
smk	108	85.4817	130.5183	0.0000
asb:smk	432	328.8083	535.1917	0.0000

A very clear interaction (effect modification)

$$\lambda(X, Z) = \alpha + \beta X + \gamma Z + \delta XZ = 12 + 48X + 108Z + 432XZ$$

$\alpha = 12$, baseline rate, i.e. that among non-smokers unexposed to asbestos (reference group),

$\beta = 48$ ($60 - 12$), rate difference between asbestos exposed and unexposed among non-smokers only,

$\gamma = 108$ ($= 120 - 12$), rate difference between smokers and non-smokers among only those unexposed to asbestos

$\delta =$ excess of rate difference between smokers and non-smokers among those exposed to asbestos:

$$\delta = (600 - 120) - (60 - 12) = 432$$

Model fitting

Output from computer packages will give:

- ▶ parameter estimates and SEs,
- ▶ goodness-of-fit statistics,
- ▶ fitted values,
- ▶ residuals,...

May be difficult to interpret!

Model checking & diagnostics:

- ▶ assessment whether model assumptions seem reasonable and consistent with data
- ▶ involves fitting and comparing different models

Problems in modeling

- ▶ Simple model chosen may be far from the “truth”.
- ▶ possible bias in effect estimation, — underestimation of SEs.
- ▶ Multitude of models fit well to the same data
which model to choose?
- ▶ Software easy to use:
- ▶ ... easy to fit models blindly
- ▶ ... possibility of unreasonable results

Modeling

- ▶ Modeling should not substitute, but complement crude analyses:
- ▶ Crude analyses should be seen as initial modeling steps: one or two effects in the model
- ▶ Final model for used for reporting developed mainly from subject matter knowledge
- ▶ Adequate training and experience required.
- ▶ Ask help from a professional statistician!
- ▶ **Collaboration** is the keyword.

Conclusion

Bendix Carstensen & Esa Läärä

Nordic Summerschool of
Cancer Epidemiology
Danish Cancer Society / NCU, August 2019 / January 2020

<http://BendixCarstensen.com/NSCE/2019>

concl-analysis

Concluding remarks

Epidemiologic study is a

Measurement exercise

Target is a **parameter** of interest, like

- ▶ incidence rate
- ▶ rate ratio
- ▶ rate difference
- ▶ relative risk
- ▶ difference in prevalences

Result: **Estimate** of the parameter.

Estimation and its errors

Like errors in measurement, estimation of parameter is prone to error:

$$\begin{aligned} \text{estimate} &= \text{true parameter value} \\ &+ \text{systematic error (bias)} \\ &+ \text{random error} \end{aligned}$$

- ▶ confounding, non-comparability,
- ▶ measurement error, misclassification,
- ▶ non-response, loss to follow-up,

Conclusion (concl-analysis)

147/ 149

Recommendations

- ▶ de-emphasize inferential statistics in favor of pure data descriptors: graphs and tables
- ▶ adopt statistical techniques based on realistic probability models
- ▶ subject the results of these to influence and sensitivity analysis.

Conclusion (concl-analysis)

148/ 149

Conclusion

“In presenting and discussing the results of an observational study the greatest emphasis should be placed on bias and confounding.”
(Brennan and Croft 1994)

Motto (Campbell & Machin 1983):

**STATISTICS is about
COMMON SENSE and
GOOD DESIGN!**

Conclusion (concl-analysis)

149/ 149